The short version
6 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fosphenytoin Sodium
Fosphenytoin Sodium · FOSPHENYTOIN SODIUM 50 mg/mL · Injection, Solution · Intramuscular; Intravenous · West-Ward Pharmaceuticals Corp
NDC 00143-9782-10 · 10 VIAL in 1 PACKAGE / 10 mL in 1 VIAL · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $170.71 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA078765
- TE code
- AP
- Approval date
- Dec 2, 2009
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedApr 13, 2012West-ward Pharmaceutical Corp. — Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.
- Class II · TerminatedApr 13, 2012West-ward Pharmaceutical Corp. — Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.
Manufacturers of Fosphenytoin Sodium (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Gland Pharma Limited | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Pfizer Laboratories Div Pfizer Inc | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Fresenius Kabi USA, LLC | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., Usa | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| West-Ward Pharmaceuticals Corp | FOSPHENYTOIN SODIUM 50 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Fosphenytoin Sodium — NDC 00143-9782-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00143978210.
Free to cite with attribution — see how the data is put together.